Conclusion:
Even though previous studies suggested favorable outcome for COVID-19
infection among patients with hemoglobinopathies. SCD remains at risk of
acute deterioration even in the absence of any COVID-19 characteristic
symptoms. Thus, close monitoring is necessary. ACS was mentioned before
as a presentation of COVID-19 infection in those patients, yet acute
hemolysis crisis should also be in mind. Offering RBCs exchange and
admitting patients to the ICU until they are stable plays a role in
improving prognosis and the earlier this is done the better the outcome.
We believe that more studies are needed to form a clear guideline
regarding RBCs exchange role and time of administration and the role of
HU compliance on the course of infection.